Shin Poong Pharm.Co.Ltd. Market Cap ($278.81 Million)

$278.81 Million USD  · ₩411.41 Billion KRW  · Rank #14912

Market Cap & Net Worth: Shin Poong Pharm.Co.Ltd. (019170)

Shin Poong Pharm.Co.Ltd. market cap. Shin Poong Pharm.Co.Ltd. (KO:019170) has a market capitalization of $278.81 Million (₩411.41 Billion) as of November 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #14912 globally and #484 in its home market, demonstrating a -3.69% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shin Poong Pharm.Co.Ltd.'s stock price ₩8350.00 by its total outstanding shares 49271029 (49.27 Million). Also see cash flow conversion of Shin Poong Pharm.Co.Ltd. for how efficiently the company converts equity into cash flow.

Shin Poong Pharm.Co.Ltd. Market Cap History (2015–2026)

Shin Poong Pharm.Co.Ltd. market cap history from 2015 to 2026. Data shows growth from $145.00 Million to $278.81 Million (6.43% CAGR). Check Shin Poong Pharm.Co.Ltd. stock price for real-time trading data and today's change.

Shin Poong Pharm.Co.Ltd. Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Shin Poong Pharm.Co.Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Shin Poong Pharm.Co.Ltd. growing its equity to track how rapidly the company is growing its equity base year over year.

Latest Price to Sales (P/S) Ratio

0.00x

Shin Poong Pharm.Co.Ltd.'s market cap is 0.00 times its annual revenue

Industry average: 0.57x Lower than industry average

Latest Price to Earnings (P/E) Ratio

0.05x

Shin Poong Pharm.Co.Ltd.'s market cap is 0.05 times its annual earnings

Industry average: 13.62x Lower than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $197.88 Million $194.15 Billion -$18.59 Billion 0.00x N/A
2017 $255.75 Million $185.00 Billion $904.89 Million 0.00x 0.28x
2018 $213.18 Million $187.39 Billion $2.80 Billion 0.00x 0.08x
2019 $240.78 Million $189.72 Billion $5.32 Billion 0.00x 0.05x
2020 $4.13 Billion $197.75 Billion $5.00 Billion 0.02x 0.83x
2021 $1.07 Billion $189.24 Billion -$11.58 Billion 0.01x N/A
2022 $706.20 Million $209.29 Billion -$35.38 Billion 0.00x N/A
2023 $451.44 Million $200.23 Billion -$57.33 Billion 0.00x N/A
2024 $344.25 Million $221.09 Billion -$15.39 Billion 0.00x N/A
2025 $468.80 Million $234.68 Billion $8.83 Billion 0.00x 0.05x

Competitor Companies of 019170 by Market Capitalization

Companies near Shin Poong Pharm.Co.Ltd. in the global market cap rankings as of November 4, 2026. Also see balance sheet size of Shin Poong Pharm.Co.Ltd. for a full breakdown of the balance sheet.

Key companies related to Shin Poong Pharm.Co.Ltd. by market ranking:

  • Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
  • GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
  • Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
  • Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#516 Takeda Pharmaceutical Co Ltd ADR NYSE:TAK $52.60 Billion $16.65
#536 GALDERMA GROUP AG NYSE:GALDY $50.42 Billion $46.55
#591 Jiangsu Hengrui Medicine Co Ltd SHG:600276 $45.45 Billion CN¥48.69
#618 Takeda Pharmaceutical Company Limited F:TKDA $43.60 Billion €18.50

Market Capitalization of Shin Poong Pharm.Co.Ltd. (2015–2026)

Market capitalization of Shin Poong Pharm.Co.Ltd. from 2015 to today. Between 2015 and today, Shin Poong Pharm.Co.Ltd.'s market cap moved from $145.00 Million to $ 278.81 Million, with a yearly change of 6.43%.

Year Market Cap Change (%)
2026 ₩278.81 Million -40.53%
2025 ₩468.80 Million +36.18%
2024 ₩344.25 Million -23.74%
2023 ₩451.44 Million -36.08%
2022 ₩706.20 Million -33.80%
2021 ₩1.07 Billion -74.15%
2020 ₩4.13 Billion +1614.23%
2019 ₩240.78 Million +12.95%
2018 ₩213.18 Million -16.64%
2017 ₩255.75 Million +29.24%
2016 ₩197.88 Million +36.47%
2015 ₩145.00 Million --

End of Day Market Cap According to Different Sources

On Nov 3rd, 2026 the market cap of Shin Poong Pharm.Co.Ltd. was reported to be:

Source Market Cap
Yahoo Finance $278.81 Million USD
MoneyControl $278.81 Million USD
MarketWatch $278.81 Million USD
marketcap.company $278.81 Million USD
Reuters $278.81 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Shin Poong Pharm.Co.Ltd.

KO:019170 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$278.81 Million
₩411.41 Billion KRW
Market Cap Rank
#14912 Global
#484 in Korea
Share Price
₩8350.00
Change (1 day)
+0.00%
52-Week Range
₩7210.00 - ₩15340.00
All Time High
₩197211.54
About

Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more